Evidence map›Paper›PMID 35913444›Full record

ArticleTurkish journal of urology2022

What Is Your Choice for Androgen Deprivation Therapy in Metastatic Prostate Carcinoma: Surgical or Medical?

Huseyin Salih Semiz, Erdem Kisa, Eda Caliskan Yildirim, Elif Atag, Mehmet Emin Arayici, Talha Muezzinoglu, Aziz Karaoglu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Huseyin Salih SemizDepartment of Medical Oncology, Dokuz Eylül University, Institute of Oncology, İzmir, Turkey.
Erdem KisaDepartment of Urology, Tepecik Education and Research Hospital, İzmir, Turkey.
Eda Caliskan YildirimDivision of Medical Oncology, Department of Internal Medicine, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey.
Elif AtagDepartment of Medical Oncology, Haydarpaşa Education and Research Hospital, İstanbul, Turkey.
Mehmet Emin ArayiciDepartment of Preventive Oncology, Dokuz Eylül University, Institute of Health Sciences, İzmir, Turkey.
Talha MuezzinogluDepartment of Urology, Manisa Celal Bayar University Faculty of Medicine, Manisa, Turkey.
Aziz KaraogluDepartment of Medical Oncology, Dokuz Eylül University, Institute of Oncology, İzmir, Turkey.
Dokuz Eylül University · TRHaydarpaşa Numune Eğitim ve Araştırma Hastanesi · TRIzmir Tepecik Eğitim ve Araştırma Hastanesi · TRManisa Celal Bayar University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAt the time of diagnosis, approximately 16.5% of prostate cancer patients are metastatic. The main framework of metastatic prostate cancer treatment is androgen deprivation therapy, which is performed surgically or medically. The aim of this study is to evaluate the attitudes of medical oncologists and urologists about orchiectomy as androgen deprivation therapy. MATERIAL AND

methodsA total of 387 physicians working in the Departments of Urology (n=217) and Medical Oncology (n=170) were included in this descriptive study. Data were collected through an electronic survey.

resultsOnly 7.5% of participants indicated that they offered surgical castration to their patients. Urologists preferred surgical castration more than oncologists for the treatment of metastatic castration-sensitive prostate carcinoma (P=.003). The reasons why medical oncologists preferred surgical castration less are that it is an invasive procedure, has risk of morbidity and mortality, high cost of hospitalization, and may cause deterioration of the patient's body image (P < .05).

conclusionThis study showed that physicians were less likely to perform orchiectomy as an androgen deprivation therapy. Although the most important reason for this is the patient preference, the biased presentation of treatment options to patients, the lack of knowledge of physicians about orchiectomy, and the effect of the pharmaceutical industry should also be kept in mind.

Identifiers

PMID35913444
PMCPMC9612692
OpenAlexW4288096077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.